These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1659695)

  • 1. Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells.
    Le Bot MA; Glaise D; Kernaleguen D; Ratanasavanh D; Carlhant D; Riche C; Guillouzo A
    Pharmacol Res; 1991 Oct; 24(3):243-52. PubMed ID: 1659695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intracellular accumulation, retention, and distribution of anthracyclines in a multidrug-resistant variant K562r].
    Hu X; Chen WY
    Zhongguo Yao Li Xue Bao; 1994 May; 15(3):275-9. PubMed ID: 7976387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
    Kuffel MJ; Reid JM; Ames MM
    Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture.
    Ballet F; Robert J; Bouma ME; Vrignaud P; Infante R
    Pharmacol Res Commun; 1986 Apr; 18(4):343-7. PubMed ID: 3461487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Int J Clin Pharmacol Ther; 1998 Feb; 36(2):89-92. PubMed ID: 9520154
    [No Abstract]   [Full Text] [Related]  

  • 8. Human cytosolic sulfotransferase SULT1C4 mediates the sulfation of doxorubicin and epirubicin.
    Luo L; Zhou C; Hui Y; Kurogi K; Sakakibara Y; Suiko M; Liu MC
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):163-6. PubMed ID: 26948952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
    Salvatorelli E; Menna P; Lusini M; Covino E; Minotti G
    J Pharmacol Exp Ther; 2009 Apr; 329(1):175-84. PubMed ID: 19144686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-phase extraction and optimized separation of doxorubicin, epirubicin and their metabolites using reversed-phase high-performance liquid chromatography.
    Nicholls G; Clark BJ; Brown JE
    J Pharm Biomed Anal; 1992; 10(10-12):949-57. PubMed ID: 1298402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decomposition of mitomycin and anthracycline cytostatics in cell culture media.
    Beijnen JH; Van der Nat JM; Labadie RP; Underberg WJ
    Anticancer Res; 1986; 6(1):39-43. PubMed ID: 3082277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
    Schott B; Robert J
    Biochem Pharmacol; 1989 Nov; 38(22):4069-74. PubMed ID: 2597184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial biotransformations of daunorubicin to aglycones by rat liver microsomes.
    Schwartz HS; Parker NB
    Cancer Res; 1981 Jun; 41(6):2343-8. PubMed ID: 7237433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
    Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.